Souhaitez-vous accéder aux communiqués récents ?

Garching / Munich, Germany, and Breda, the Netherlands, September 24, 2025 – ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, and TerThera BV, a leading...

BetaGlue Therapeutics Announces the Appointment of Alexis Peyroles as New Chief Executive Officer

Garching / Munich, Germany, September 16, 2025 – ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, today announced that it will unveil dosimetry data from its...

Basel, Switzerland / Munich, Germany, September 16, 2025 – NUCLIDIUM AG, a clinical-stage radiopharmaceutical company developing a proprietary copper-based theranostic platform, today announced that...

Dublin, Sept. 08, 2025 (GLOBE NEWSWIRE) -- The "Brachytherapy Market Forecast 2025-2030" has been added to ResearchAndMarkets.com's offering. The Brachytherapy Market is set for significant...

Garching / Munich, Germany, September 4, 2025 – ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, today announced its participation in the Oppenheimer Annual...

Garching / Munich, Germany, August 19, 2025 – ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, today announced that further data on efficacy, safety and...

Proceeds will fund further clinical development of the company’s true theranostic pipeline and expansion of the global production and manufacturing network for copper-based...

61Cu-NuriPro™ detected more lesions up to 4 hours post-administration in 50% of patients, not visualized by 18F-piflufolastat PET1,2 Dosimetry data highlight favorable tumor-to-background ratio with...

New study arm (Part D) is part of the broad clinical development plan of the ITM-91/ITM-94 theranostic program in patients with Carbonic Anhydrase IX (CAIX)-expressing tumors Part D builds on...